MLTX NASDAQ
MoonLake Immunotherapeutics
1W: +21.1%
1M: -1.9%
3M: -36.9%
YTD: -1.2%
1Y: +24.8%
3Y: -79.0%
5Y: +18.1%
$11.93
+0.12 (+1.02%)
After Hours: $12.21 (+0.28, +2.31%)
Weekly Expected Move ±10.7%
$9
$11
$12
$13
$14
Credit Risk of going bust: higher than 60% of companies Debt: 9.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.16 (down 99%), MoonLake Immunotherapeutics would be worth roughly what it owes.
Total debt $101.5M against a stock market value of $1.01B.
Distance to default 4.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $101.5M against a stock market value of $1.01B.
Distance to default 4.27 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $49.8M (short-term plus half of long-term), stock volatility 70.4%; Altman Z'' 2.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-10-04
Earliest Filing
2023-06-29
Latest Filing
partner: 3
target: 1
Counterparties (Filed by MLTX)
4 relationshipsCompanies named in MLTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Research Cooperation Technologies, Inc. | — | partner | Licensor of manufacturing process patents and know-how | 2023-06-29 | View |
| MHKDG | — | partner | Counterparty in previous license agreement replaced by new RCT agreement | 2023-06-29 | View |
| MoonLake Immunotherapeutics AG | MLTX | target | Target company in the business combination with Helix Acquisition Corp. | 2021-10-04 | View |
| Helix Holdings LLC | HLX | partner | Sponsor of Helix Acquisition Corp. and party to the Business Combination Agreement. | 2021-10-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-30 | Other Events | View | |
| 2026-08-10 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-07-15 | Other Events | View | |
| 2026-06-25 | Material Agreement; Exhibits | Agreement | View |
| 2026-06-22 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-09 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-06-01 | Material Agreement | Agreement | View |
| 2026-05-11 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-02-23 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Creation of | Agreement | View |
| 2026-01-08 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-05 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-09-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-05 | Results of Operations and Financial Condition | View | |
| 2025-06-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-12 | Results of Operations and Financial Condition | View | |
| 2025-04-29 | Regulation FD Disclosure | View | |
| 2025-04-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-02-26 | Results of Operations and Financial Condition | View | |
| 2024-12-18 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR